Creso Pharma’s Mernova receives initial purchase order
Creso Pharma Limited’s (ASX:CPH; FRA:1X8) wholly-owned subsidiary, Mernova Medicinal Inc. (Mernova), a Licensed Producer of cannabis products with its operations based in Nova Scotia, Canada, has received an initial purchase order (PO) valued at C$180,000.
The order was received from the Nova Scotia Liquor Corporation (NSLC) for the purchase of two of its premium strains, HPG13 and Lemon Haze.
The NSLC is operated by the Nova Scotia Provincial government and is the sole distributor of retail cannabis in Nova Scotia.
This important milestone marks the imminent launch of Mernova’s Ritual Green brand of high-quality cannabis products into Canada’s rapidly growing recreational markets.
Entering Canada’s retail markets diversifies Mernova’s revenue streams and builds on an established and growing wholesale product sales pipeline.
Ritual Green to be sold through NSLC stores and e-commerce platforms
Mernova’s retail recreational cannabis products will be launched under the brand name ‘Ritual Green’ and will initially be sold through the Nova Scotia Liquor Corporation’s (NSLC) stores and e-commerce platform.
The first product available to recreational customers will be Mernova’s high-quality dried flower in its natural form.
Additional high-quality products will be added to the product line as they become available.
The Ritual Green HPG13 product is illustrated below.
Further recreational and medicinal opportunities for Mernova
Highlighting the significance of this development in terms of building a strong brand in the group’s home province, Mernova’s managing director Jack Yu said, “Receiving this initial PO is the first step to Mernova establishing itself as a trusted supplier of high-quality, locally grown, artisanal cannabis products to the NSLC.
“To meet the supply chain demands of the NSLC and other provincial purchasers, we are adjusting our grow scheduling, while simultaneously ramping up production of our highest quality strains.
“We plan on taking full advantage of this opportunity to build our brand and brand loyalty, in our home province of Nova Scotia and I look forward to providing further updates in the near-term.”
Creso Pharma’s management said that it will continue to provide regular updates on retail and wholesale sales, as well as expansion opportunities available to Mernova as referred to by Yu.
Mernova is also making considerable progress towards securing EU (European Union) Good Manufacturing Practice (GMP) certification, a development that could be a significant share price catalyst for Creso Pharma.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.